Drug Trial Radar · NCT05390905
A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment
Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
387
Actual
Start
Jun 8, 2022
Primary completion
Dec 16, 2022
Study completion Mar 28, 2023
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, placebo/active-controlled study. About 387 subjects undergoing elective abdominal operation under general anesthesia are planned to be enrolled and randomized into the HSK21542 group (129 subjects), tramadol group (129 subjects), and placebo group (129 subjects).
Conditions
- Postoperative Analgesia
Interventions
HSK21542 InjectionDrug
1μg/kg/dose
Tramadol hydrochlorideDrug
50mg/dose
placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sum of Pain Intensity Differences (SPID) in the HSK21542 group and the placebo groupTime frame: From administration until 24 hours after administration
- Sum of Pain Intensity Differences (SPID) in tramadol group and the placebo groupTime frame: From administration until 24 hours after administration
- Sum of Pain Intensity Differences (SPID) in the HSK21542 group and the tramadol groupTime frame: From administration until 24 hours after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College, Huazhong U
Wuhan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.